S&P 500
7,614.20
-0.11%
Dow Jones
51,331.00
-0.08%
Nasdaq 100
30,633.50
-0.27%
Russell 2000
2,927.38
-0.19%
FTSE 100
10,381.80
-0.06%
Nikkei 225
68,209.20
+1.05%

Health and Healthcare

OncoGenex Prices Secondary Offering, Shares Fall (OGXI)

Photo of Paul Ausick
By Paul Ausick Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Invalid Image
Cancer therapy developer OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI) has priced a secondary offering of 4.165 million common shares at $12.00/share, a discount of 31% to yesterday’s closing price of $17.43. Needless to say the shares are getting pounded today.

OncoGenex expects to realize about $46.8 million from the offering, net of fees and expenses. Leerink Swann LLC and Stifel Nicolaus Weisel are acting as joint book-running managers and Lazard Capital Markets LLC and William Blair & Company, L.L.C. are acting as co-managers. The underwriters have a 30-day over-allotment option of 624,750 shares.

The company did not specify how it plans to use the proceeds from the sale.

Shares are down nearly -20% at $13.99 in a 52-week range of $8.63-$18.99.

DISCLOSURE:
INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org). Advisory services are offered by SoFi Wealth LLC, an SEC-registered investment adviser. Information about SoFi Wealth’s advisory operations, services, and fees is set forth in SoFi Wealth’s current Form ADV Part 2 (Brochure), a copy of which is available upon request and at www.adviserinfo.sec.gov. Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 30 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees. Investing in alternative investments and/or strategies may not be suitable for all investors and involves unique risks, including the risk of loss. An investor should consider their individual circumstances and any investment information, such as a prospectus, prior to investing. Interval Funds are illiquid instruments, the ability to trade on your timeline may be restricted. Brokerage and Active investing products offered through SoFi Securities LLC, Member FINRA(www.finra.org) /SIPC(www.sipc.org). There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event. Options involve risks, including substantial risk of loss and the possibility an investor may lose the entire investment Before trading options please review the Characteristics and Risks of Standardized Options  Investing in an Initial Public Offering (IPO) involves substantial risk, including the risk of loss. Further, there are a variety of risk factors to consider when investing in an IPO, including but not limited to, unproven management, significant debt, and lack of operating history. For a comprehensive discussion of these risks please refer to SoFi Securities’ IPO Risk Disclosure Statement This should not be considered a recommendation to participate in IPOs and investors should carefully read the offering prospectus to determine whether an offering is consistent with their investment objectives, risk tolerance, and financial situation. New offerings generally have high demand and there are a limited number of shares available for distribution to participants. Many customers may not be allocated shares and share allocations may be significantly smaller than the shares requested in the customer’s initial offer (Indication of Interest). For more information on the allocation process please visit IPO Allocation.
Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Jon C. Ogg |

Top Active Trader Alert Stocks (ABK, AAPL, ARMH, CTIC, CWTR, INFN, MSFT, OGXI)

Active traders and day traders have many stocks to choose from this Wednesday morning.  We are tracking news and moves…

6 Biotechs Seriously on the Move
Chris Lange |

6 Biotechs Seriously on the Move

A few biotech companies made fantastic runs in Thursday’s session. We have included information about each company, as well as…

Paul Ausick |

Busiest IPO Week of the Year: 14 Companies on the Calendar

ThinkstockFour of last week’s six initial public offering (IPO) candidates successfully launched into the public equity markets, but the reception…

4 Biotech IPOs Hoping to Become First U.S. IPO of 2016
Paul Ausick |

4 Biotech IPOs Hoping to Become First U.S. IPO of 2016

To say that the month of January was a bust for initial public offerings (IPOs) is an understatement. January was…

Week of November 9 Sees 9 IPOs on the Calendar
Paul Ausick |

Week of November 9 Sees 9 IPOs on the Calendar

Two holdovers and seven new entries are on the coming week's IPO calendar, including four biotechs and two financial companies.

3 New Biotech IPOs on Calendar for Next Week
Paul Ausick |

3 New Biotech IPOs on Calendar for Next Week

Blank-check company KLR Energy Acquisition Corp. (NASDAQ: KLREU) completed its initial public offering (IPO) last Friday, the first successful IPO…

Paul Ausick |

8 IPOs on the Calendar for Week of July 13

The initial public offering (IPO) calendar heats up again in the week of July 13, with eight offerings scheduled to…

Paul Ausick |

Health Care Dominates IPO Schedule for First Week of February

Including one holdover from last week, there are 12 IPOs on the calendar for the first week of February.

Paul Ausick |

7 Health Care IPOs on Next Week’s Calendar

ThinkstockLast week was not a standout for initial public offerings (IPOs). There were three on the calendar, and only a…

Top Gaining Stocks

Hewlett Packard Enterprise
HPE • Vol: 153,197,465
Enphase Energy
ENPH • Vol: 8,360,053
Corning
GLW • Vol: 18,152,646
Alexandria Real Estate Equities
ARE • Vol: 4,337,015
Aptiv
APTV • Vol: 6,761,325

Top Losing Stocks

Trade Desk
TTD • Vol: 21,905,513
Intuit
INTU • Vol: 7,383,018
Coterra Energy
CTRA • Vol: 73,319,495
Cboe Global Markets
CBOE • Vol: 5,000,011
HP
HPQ • Vol: 29,259,826